Shariaportfolio Inc. Buys 846 Shares of Becton, Dickinson and Company (NYSE:BDX)

Shariaportfolio Inc. lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 11.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,163 shares of the medical instruments supplier’s stock after purchasing an additional 846 shares during the quarter. Becton, Dickinson and Company accounts for 1.0% of Shariaportfolio Inc.’s investment portfolio, making the stock its 17th largest holding. Shariaportfolio Inc.’s holdings in Becton, Dickinson and Company were worth $1,908,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. WR Wealth Planners LLC increased its stake in shares of Becton, Dickinson and Company by 1.4% in the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after purchasing an additional 42 shares in the last quarter. Ridgewood Investments LLC lifted its stake in Becton, Dickinson and Company by 1.5% in the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after acquiring an additional 43 shares during the period. Key Client Fiduciary Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 2.6% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after purchasing an additional 43 shares in the last quarter. Clear Creek Financial Management LLC raised its position in shares of Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after acquiring an additional 44 shares in the last quarter. Finally, Edge Capital Group LLC lifted its position in Becton, Dickinson and Company by 3.1% during the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock valued at $384,000 after buying an additional 48 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX opened at $231.27 on Wednesday. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $269.52. The firm has a market capitalization of $66.84 billion, a PE ratio of 50.94, a P/E/G ratio of 1.91 and a beta of 0.42. The business’s 50 day moving average price is $235.07 and its 200-day moving average price is $235.57. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.96 earnings per share. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.1 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BDX shares. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup lowered their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a report on Wednesday, July 10th. Evercore ISI dropped their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Raymond James lowered their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Finally, The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $279.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.